Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.

Abstract:

UNLABELLED

Endoscopic variceal ligation plus beta-blockers (EVL+BB) is currently recommended for variceal rebleeding prophylaxis, a recommendation that extends to all patients with cirrhosis with previous variceal bleeding irrespective of prognostic stage. Individualizing patient care is relevant, and in published studies on variceal rebleeding prophylaxis, there is a lack of information regarding response to therapy by prognostic stage. This study aimed at comparing EVL plus BB with monotherapy (EVL or BB) on all-source rebleeding and mortality in patients with cirrhosis and previous variceal bleeding stratified by cirrhosis severity (Child A versus B/C) by means of individual time-to-event patient data meta-analysis from randomized controlled trials. The study used individual data on 389 patients from three trials comparing EVL plus BB versus BB and 416 patients from four trials comparing EVL plus BB versus EVL. Compared with BB alone, EVL plus BB reduced overall rebleeding in Child A (incidence rate ratio 0.40; 95% confidence interval, 0.18-0.89; P = 0.025) but not in Child B/C, without differences in mortality. The effect of EVL on rebleeding was different according to Child (P for interaction <0.001). Conversely, compared with EVL, EVL plus BB reduced rebleeding in both Child A and B/C, with a significant reduction in mortality in Child B/C (incidence rate ratio 0.46; 95% confidence interval, 0.25-0.85; P = 0.013).

CONCLUSION

Outcomes of therapies to prevent variceal rebleeding differ depending on cirrhosis severity: in patients with preserved liver function (Child A), combination therapy is recommended because it is more effective in preventing rebleeding, without modifying survival, while in patients with advanced liver failure (Child B/C), EVL alone carries an increased risk of rebleeding and death compared with combination therapy, underlining that BB is the key element of combination therapy. (Hepatology 2017;66:1219-1231).

© 2017 by the American Association for the Study of Liver Diseases.

Keywords:

References: Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet. 2003;361:952–954.
de Franchis R Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–768.
Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J. Portal Hypertensive Bleedingin Cirrhosis: Risk Stratification, Diagnosis and Management - 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65:310–85.
Cheung J, Zeman M, van Zanten SV, et al. Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. Aliment Pharmacol Ther. 2009;30:577–588.
Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149:109–122.
Puente A, Hernández-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int. 2014;34:823–833.
Ripoll C, Bari K, Garcia-Tsao G. Serum albumin can identify patients With compensated cirrhosis with a good prognosis. J Clin Gastroenterol. 2015;49:613–9.
D’Amico G, García-Tsao G, Pagliaro L. Natural history and prgnostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006;44:217–231.
Garcia-Tsao G. The Child-Turcotte classification: From Gestalt to sophisticated statistics and back. Dig Dis Sci. 2016;61:3102–3104.
Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313:1657–1665.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.
Rabe-Hesketh S, Skrondal A. Classical latent variable models for medical research. Stat Methods Med Res. 2008;17:5–32.
Merlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health. 2006;60:290–297.
Abdel-Rhaim AY, Abdel-Ghany MS, El-Kholy B. Band ligation alone versus band ligation and propranolol in the management of bleeding esophageal varices (Abstract) Am J Gastroenterol. 2000;95:2442.
Sollano JD, Melchor RJ, Chan M, et al. Propranolol prevents rebleeding after variceal ligation. Gastrointest Endosc. 2002;53:AB143.
Lo GH, Lai KH, Cheng JS, et al. The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc. 2001;53:579–584.
Villanueva C, Aracil C, Colomo A, et al. Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol plus ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther. 2009;29:397–408.
Ahmad I, Khan A, Alam A, et al. Propranolol, isosorbide mononitrate and endoscopic band ligation – alone or in varying combinations for the prevention of esophageal variceal rebleeding. J Coll Physicians Surg Pak. 2009;19:283–286.
Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology. 2009;137:892–901.
De la Peña J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology. 2005;41:572–8.
Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology. 2000;32:461–565.
Lo GH, Chen WC, Chan HH, et al. A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol. 2009;24:982–987.
Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicenter randomized controlled trial. Gut. 2009;58:1144–1150.
Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323:42–46.
de Franchis R Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.
Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of oesophageal variceal bleeding. A meta-analysis. Ann Intern Med. 1995;123:280–287.
Lo GH, Chen WC, Lin CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology. 2008;48:580–587.
Riley RD, Steyerberg EW. Meta-analysis of a binary outcome using individual participant data and aggregate data. Res Synth Methods. 2010;1:2–19.
Gore SM, Pocock SJ, Kerr GR. Regression Models and Non-Proportional Hazards in the Analysis of Breast Cancer Survival. J R Stat Soc C Appl Stat. 1984;33:176–195.

Authors

• Juan G Abraldes |
• Irfan Ahmad |
• Agustín Albillos |
• David Arroyo |
• Jaime Bosch |
• Joaquin De-la-Peña |
• Juan-Carlos Garcia-Pagan |
• Guadalupe Garcia-Tsao |
• Gin-Ho Lo |
• Javier Martínez |
• Shiv Sarin |
• Barjesh Sharma |
• Javier Zamora |